Tyrosine kinase inhibitors (TKIs) revolutionized treatment of chronic myeloid leukemia (CML). However, the rst months of therapy are crucial, as optimal response is dened as the achievement of molecular milestones at 3, 6 and 12 months (mo.) and as many toxicities, also causing a TKI switch, are more frequent in the 1st year
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study
Mulas, Olga;Caocci, Giovanni;Specchia, Giorgina;
2021-01-01
Abstract
Tyrosine kinase inhibitors (TKIs) revolutionized treatment of chronic myeloid leukemia (CML). However, the rst months of therapy are crucial, as optimal response is dened as the achievement of molecular milestones at 3, 6 and 12 months (mo.) and as many toxicities, also causing a TKI switch, are more frequent in the 1st year
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PDF abstracts 1-s2.0-S0006497121034595-main.pdf
accesso aperto
Tipologia:
versione editoriale (VoR)
Dimensione
438.82 kB
Formato
Adobe PDF
|
438.82 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
